CAR-T cell therapies have transformed cancer treatment, though complex manufacturing limits patient access. Recent efforts focus on rapid manufacturing to produce potent, persistent CAR-T cells more efficiently. Early clinical data from rapid-CAR-T trials show strong anti-tumor responses at lower doses. At Lonza, we developed a 72-hour rapid manufacturing process on the Cocoon® Platform, automating T cell selection, activation, transduction, and expansion. This functionally closed, pre-programmed system minimizes manual steps, enhances consistency, and reduces labor and costs. By streamlining production, the Cocoon® Platform supports broader accessibility to CAR-T therapies, advancing clinical impact and scalability of this promising treatment modality.